O. Davies

3.2k total citations
44 papers, 676 citations indexed

About

O. Davies is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, O. Davies has authored 44 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Rheumatology, 11 papers in Immunology and 7 papers in Genetics. Recurrent topics in O. Davies's work include Rheumatoid Arthritis Research and Therapies (16 papers), Spondyloarthritis Studies and Treatments (14 papers) and Psoriasis: Treatment and Pathogenesis (11 papers). O. Davies is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Spondyloarthritis Studies and Treatments (14 papers) and Psoriasis: Treatment and Pathogenesis (11 papers). O. Davies collaborates with scholars based in United Kingdom, United States and Germany. O. Davies's co-authors include Robert Landewé, Désirée van der Heijde, Bengt Hoepken, T. Nurminen, Walter P. Maksymowych, Lars Bauer, Xenofon Baraliakos, Martín Rudwaleit, Atul Deodhar and Natasha de Peyrecave and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

O. Davies

39 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
O. Davies United Kingdom	15	541	283	207	76	52	44	676
Shelly Kafka United States	12	423 0.8×	235 0.8×	206 1.0×	59 0.8×	73 1.4×	40	733
Joost M. Meijer Netherlands	17	250 0.5×	103 0.4×	202 1.0×	271 3.6×	301 5.8×	47	888
Shannon O’Neill United States	12	151 0.3×	564 2.0×	33 0.2×	61 0.8×	47 0.9×	18	855
Philipp Kastner Australia	6	176 0.3×	69 0.2×	108 0.5×	76 1.0×	43 0.8×	18	322
Megha Rajasekhar United Kingdom	9	187 0.3×	270 1.0×	119 0.6×	11 0.1×	13 0.3×	16	503
Pankit Vachhani United States	12	23 0.0×	106 0.4×	365 1.8×	103 1.4×	17 0.3×	81	741
Birgitta S. Breur-Vriesendorp Netherlands	13	141 0.3×	459 1.6×	141 0.7×	37 0.5×	30 0.6×	22	595
Esra Özcan United States	14	101 0.2×	429 1.5×	35 0.2×	21 0.3×	22 0.4×	25	713
Ulrich Wesselmann Germany	10	118 0.2×	60 0.2×	46 0.2×	90 1.2×	171 3.3×	17	641
H P Brezinschek Austria	6	260 0.5×	223 0.8×	138 0.7×	94 1.2×	61 1.2×	9	529

Countries citing papers authored by O. Davies

Since Specialization

Citations

This map shows the geographic impact of O. Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Davies more than expected).

Fields of papers citing papers by O. Davies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Davies. The network helps show where O. Davies may publish in the future.

Co-authorship network of co-authors of O. Davies

This figure shows the co-authorship network connecting the top 25 collaborators of O. Davies. A scholar is included among the top collaborators of O. Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Davies. O. Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blauvelt, Andrew, April W. Armstrong, Joseph F. Merola, et al.. (2024). Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials. Journal of the American Academy of Dermatology. 91(1). 72–81. 6 indexed citations

Lebwohl, Mark, Joseph F. Merola, Bruce Strober, et al.. (2024). Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. Journal of the American Academy of Dermatology. 91(2). 281–289. 2 indexed citations

Gordon, Kenneth B., Richard G. Langley, Richard B. Warren, et al.. (2023). Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology. 190(4). 477–485. 14 indexed citations

Blauvelt, Andrew, April W. Armstrong, Joseph F. Merola, et al.. (2023). Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders. SKIN The Journal of Cutaneous Medicine. 7(6). s300–s300.

DeMicco, Frederick J., et al.. (2021). COVID-19 Impact on the Future of Hospitality and Travel. Journal of Hospitality & Tourism Research. 45(5). 911–914. 17 indexed citations

Junker, Kerstin, Andrea Spickett, O. Davies, Raymond Jansen, & Boris R. Krasnov. (2021). Gastrointestinal nematodes in two galliform birds from South Africa: patterns associated with host sex and age. Parasitology Research. 120(9). 3229–3244. 1 indexed citations

Landewé, Robert, Désirée van der Heijde, Maxime Dougados, et al.. (2020). Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Annals of the Rheumatic Diseases. 79(7). 920–928. 47 indexed citations

Heijde, Désirée van der, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2018). Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases. 77(5). 699–705. 90 indexed citations

Landewé, Robert, T. Nurminen, O. Davies, & Dominique Baeten. (2018). A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’. Arthritis Research & Therapy. 20(1). 209–209. 21 indexed citations

10.

Heijde, Désirée van der, Maxime Dougados, Robert Landewé, et al.. (2016). SAT0375 Certolizumab Pegol for The Treatment of Axial Spondyloarthritis: 4-Year Outcomes from The Rapid-AXSPA Trial. Annals of the Rheumatic Diseases. 75. 803–803. 1 indexed citations

11.

Rudwaleit, Martín, James T. Rosenbaum, Robert Landewé, et al.. (2016). Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. Arthritis Care & Research. 68(6). 838–844. 65 indexed citations

12.

Weinblatt, Michael E., Roy Fleischmann, Ronald van Vollenhoven, et al.. (2015). Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research & Therapy. 17(1). 325–325. 12 indexed citations

13.

Rosenbaum, J. T., Martín Rudwaleit, Robert Landewé, et al.. (2014). Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.. Data Archiving and Networked Services (DANS). 66. 1 indexed citations

14.

Davies, O., et al.. (2014). Working Patterns in Wales: Gender, Occupations and Pay. ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam). 2 indexed citations

15.

Furst, Daniel E., et al.. (2014). Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis. Arthritis Care & Research. 67(2). 151–160. 14 indexed citations

16.

Davies, O., et al.. (2013). Evaluating the Foundation Phase: the outcomes of Foundation Phase pupils (Report 1). ORCA Online Research @Cardiff (Cardiff University). 7 indexed citations

17.

Felstead, Alan, O. Davies, & Samuel E. Jones. (2013). Skills and the quality of work in Wales, 2006-2012: Main results. ORCA Online Research @Cardiff (Cardiff University). 2 indexed citations

18.

Choy, Ernest, Frank McKenna, Jiří Vencovský, et al.. (2012). Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Lara D. Veeken. 51(7). 1226–1234. 67 indexed citations

19.

Weinblatt, M., R Fleischmann, Ronald van Vollenhoven, et al.. (2011). Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations

20.

Keystone, Edward, Jeffrey R. Curtis, Roy Fleischmann, et al.. (2011). Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial. The Journal of Rheumatology. 38(6). 990–996. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact